1476776-55-2

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl (S)-3-(4-bromophenyl)piperidine-1-carboxylate is used as an intermediate for the synthesis of Niraparib, a novel oral PARP inhibitor for the treatment of BRCA-1 and -2 mutant tumors. Its role in the development of this therapeutic agent is essential, as it contributes to the efficacy of Niraparib in targeting and treating these specific types of cancer.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1476776-53-0 (S)-3-(4-bromophenyl)piperidin-1-ium 4-methylbenzenesulfonate 
• 1335523-82-4 4-(3S-piperidine-3-yl)bromobenzene 
• 1476776-62-1 C₁₁H₁₆BrNO 
• 1476776-64-3 (S)-tert-butyl (2-(4-bromophenyl)-5-hydroxypentyl)carbamate 
• 1476776-66-5 (S)-4-(4-bromophenyl)-5-((tert-butoxycarbonyl)amino)pentyl methanesulfonate 
• 108-86-1 bromobenzene 
• 1476776-61-0 C₁₁H₁₃BrO₂ 
• 59349-71-2 (S)-3-phenylpiperidine hydrochloride 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 204851-47-8 (4S)-4-benzyl-3-(2-(4-bromophenyl)acetyl)oxazolidin-2-one 
• 1476776-44-9 (S)-5-(4-bromophenyl)piperidin-2-one 
• 1476776-40-5 isopropyl 4-(4-bromophenyl)-5-oxopentanoate 
• 1476776-39-2 isopropyl 3-(2-(4-bromophenyl)oxiran-2-yl)-propanoate 

Downstream Products

• 1038915-73-9 2-[4-((3S)-3-piperidinyl)phenyl]-2H-indazole-7-carboxamide p-toluenesulfonic acid salt 
• 1196713-67-3 2-[4-((3S)-(tertbutoxycarbonyl)piperidin-3-yl)phenyl]-2H-indazole-7-carboxylic acid methyl ester 
• 1038915-60-4 (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine 

Relevant academic research and scientific papers

DEUTERATED (S)-2-(4-(PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE

A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; whereinY1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9', Y10, Y10', Y11,

A nepal pulls handkerchief nepal and intermediate preparation method and intermediate compounds (by machine translation)

The invention discloses a method for preparing nepal pulls handkerchief nepal intermediate, represented by the formula, comprising the following steps: to (S)- oxazolidone to the bromobenzene with acetic acid as the starting material, to amide condensation, Michael addition, lipid amide reduction, sulfuryl fat synthesis, ammoniation ring, with the reaction of the organic acid salt, can be. The invention also discloses the preparation of nepal pulls handkerchief nepal and intermediates therefor. Preparation method of the invention low cost, easy availability of raw materials, the yield is high, it is suitable for industrial production. (by machine translation)

Preparation method of niraparib tosilate monohydrate

The invention discloses a preparation method of a compound 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The method includes: carrying out Ulman reaction on 1H-indazole-7-methyl formate and (S)-3-(4-halogenophenyl)piperidine-1-tert-butyl formate to prepare 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-methyl formate, then under the conditions of ammonia gas and p-toluenesulfonic acid, preparing 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate. The invention aims to avoid the disadvantages of existing methods, shortens the preparation route, and provides the preparation method of the 2-[4-((3S)-3-piperidyl)phenyl]-2H-indazole-7-formamide tosilate monohydrate with high chiral purity, and the method has the characteristics of mild reaction and easy operation.

Preparation method of chiral intermediate of niraparib

The invention discloses a novel synthetic method for preparing a chiral intermediate of niraparib. The method comprises the following steps: taking 4-bromophenylacetic acid and chiral substituted oxazolone as starting materials; and carrying out amide condensation, Michael addition, hydrolysis, reduction and intramolecular cyclization to obtain the intermediate (VII). The preparation method is low in cost, raw materials are easily obtained, the yield is high, and the synthetic method is suitable for industrialized production.

Process development of C-N cross-coupling and enantioselective biocatalytic reactions for the asymmetric synthesis of niraparib

Process development of the synthesis of the orally active poly(ADP-ribose)polymerase inhibitor niraparib is described. Two new asymmetric routes are reported, which converge on a high-yielding, regioselective, copper-catalyzed Narylation of an indazole derivative as the late-stage fragment coupling step. Novel transaminase-mediated dynamic kinetic resolutions of racemic aldehyde surrogates provided enantioselective syntheses of the 3-aryl-piperidine coupling partner. Conversion of the C-N cross-coupling product to the final API was achieved by deprotection and salt metathesis to isolate the desired crystalline salt form.